Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry

Allan MacKenzie-Graham, Jenny Brook, Florian Kurth, Yuichiro Itoh, Cassandra Meyer, Michael J Montag, He-Jing Wang, Robert Elashoff, Rhonda R Voskuhl, Allan MacKenzie-Graham, Jenny Brook, Florian Kurth, Yuichiro Itoh, Cassandra Meyer, Michael J Montag, He-Jing Wang, Robert Elashoff, Rhonda R Voskuhl

Abstract

Introduction: Progressive gray matter (GM) atrophy is a hallmark of multiple sclerosis (MS). Cognitive impairment has been observed in 40%-70% of MS patients and has been linked to GM atrophy. In a phase 2 trial of estriol treatment in women with relapsing-remitting MS (RRMS), higher estriol levels correlated with greater improvement on the paced auditory serial addition test (PASAT) and imaging revealed sparing of localized GM in estriol-treated compared to placebo-treated patients. To better understand the significance of this GM sparing, the current study explored the relationships between the GM sparing and traditional MRI measures and clinical outcomes.

Methods: Sixty-two estriol- and forty-nine placebo-treated RRMS patients underwent clinical evaluations and brain MRI. Voxel-based morphometry (VBM) was used to evaluate voxelwise GM sparing from high-resolution T1-weighted scans.

Results: A region of treatment-induced sparing (TIS) was defined as the areas where GM was spared in estriol- as compared to placebo-treated groups, localized primarily within the frontal and parietal cortices. We observed that TIS volume was directly correlated with improvement on the PASAT. Next, a longitudinal cognitive disability-specific atlas (DSA) was defined by correlating voxelwise GM volumes with PASAT scores, that is, areas where less GM correlated with less improvement in PASAT scores. Finally, overlap between the TIS and the longitudinal cognitive DSA revealed a specific region of cortical GM that was preserved in estriol-treated subjects that was associated with better performance on the PASAT.

Conclusions: Discovery of this region of overlap was biology driven, not based on an a priori structure of interest. It included the medial frontal cortex, an area previously implicated in problem solving and attention. These findings indicate that localized GM sparing during estriol treatment was associated with improvement in cognitive testing, suggesting a clinically relevant, disability-specific biomarker for clinical trials of candidate neuroprotective treatments in MS.

Keywords: atrophy; brain; estriol; magnetic resonance imaging; multiple sclerosis; voxel-based morphometry.

© 2018 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Trial profile
Figure 2
Figure 2
Change in paced auditory serial addition test at 3 s (PASAT3) scores in all patients at baseline month 0 and on treatment at months 3, 6, 12, 18, and 24. Change in mean absolute scores at each time point as compared to baseline is shown in red for the estriol + glatiramer acetate group and in black for the placebo + glatiramer acetate group. Values are expressed as means ± standard error of the mean. Positive change in absolute scores from baseline indicates improvement
Figure 3
Figure 3
Estriol treatment‐induced sparing of gray matter. Surface renderings (top) and maximum intensity projections (bottom) of regions of significant gray matter preservation in the estriol + glatiramer acetate group as compared to the placebo + glatiramer acetate group at month 12 superimposed on the statistical parametric mapping standard glass brain. Results were corrected for multiple comparisons by controlling the false discovery rate at p ≤ 0.05
Figure 4
Figure 4
Heat map showing positive and negative correlations and their clustering in each treatment group. A graphical representation of relationship among treatment‐induced sparing volume (TIS vol), traditional MRI measures (gray matter volume (GM vol), cortical gray matter volume (cGM vol), fluid‐attenuated inversion recovery lesion volume (FLAIR vol), gadolinium‐enhancing lesion volume (Gd vol), white matter volume (WM vol), cerebrospinal fluid volume (CSF vol)), and clinical measures (paced auditory serial addition test at 3 s (PASAT3), paced auditory serial addition test at 2 s (PASAT2), timed 25‐foot walk (T25FW), nine‐hole peg test (9HPT), multiple sclerosis functional composite (MSFC), expended disability status score (EDSS)). In the heat map, yellow indicates a positive (direct) correlation and red indicates a negative (indirect) correlation between the values. (a) Heat map for the estriol + glatiramer acetate group. (b) Heat map for the placebo + glatiramer acetate group
Figure 5
Figure 5
Longitudinal cognitive disability‐specific atlas. Surface renderings (top) and maximum intensity projections (bottom) of regions of statistically significant correlation between gray matter volume change and paced auditory serial addition test at 2‐s performance change in all patients and across all time points superimposed on the statistical parametric mapping standard glass brain. All results were corrected for multiple comparisons by controlling the false discovery rate at p ≤ 0.05
Figure 6
Figure 6
Overlap of the region of treatment‐induced sparing and the longitudinal cognitive disability‐specific atlas. Surface renderings (top) and maximum intensity projections (bottom) superimposed on the statistical parametric mapping standard glass brain

References

    1. Amato, M. P. , Bartolozzi, M. L. , Zipoli, V. , Portaccio, E. , Mortilla, M. , Guidi, L. , … De Stefano, N. (2004). Neocortical volume decrease in relapsing‐remitting MS patients with mild cognitive impairment. Neurology, 63, 89–93. 10.1212/01.WNL.0000129544.79539.D5
    1. Amato, M. P. , Zipoli, V. , & Portaccio, E. (2006). Multiple sclerosis‐related cognitive changes: A review of cross‐sectional and longitudinal studies. Journal of the Neurological Sciences, 245, 41–46. 10.1016/j.jns.2005.08.019
    1. Ashburner, J. (2007). A fast diffeomorphic image registration algorithm. NeuroImage, 38, 95–113. 10.1016/j.neuroimage.2007.07.007
    1. Ashburner, J. , & Friston, K. J. (2001). Why voxel‐based morphometry should be used. NeuroImage, 14, 1238–1243. 10.1006/nimg.2001.0961
    1. Battaglini, M. , Giorgio, A. , Stromillo, M. L. , Bartolozzi, M. L. , Guidi, L. , Federico, A. , & De Stefano, N. (2009). Voxel‐wise assessment of progression of regional brain atrophy in relapsing‐remitting multiple sclerosis. Journal of the Neurological Sciences, 282, 55–60. 10.1016/j.jns.2009.02.322
    1. Bendfeldt, K. , Egger, H. , Nichols, T. E. , Loetscher, P. , Denier, N. , Kuster, P. , … Borgwardt, S. J. (2010). Effect of immunomodulatory medication on regional gray matter loss in relapsing‐remitting multiple sclerosis – A longitudinal MRI study. Brain Research, 1325, 174–182. 10.1016/j.brainres.2010.02.035
    1. Bendfeldt, K. , Kuster, P. , Traud, S. , Egger, H. , Winklhofer, S. , Mueller‐Lenke, N. , … Borgwardt, S. J. (2009). Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis ‐ A longitudinal voxel‐based morphometry study. NeuroImage, 45, 60–67. 10.1016/j.neuroimage.2008.10.006
    1. Benedict, R. H. , Weinstock‐Guttman, B. , Fishman, I. , Sharma, J. , Tjoa, C. W. , & Bakshi, R. (2004). Prediction of neuropsychological impairment in multiple sclerosis: Comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Archives of Neurology, 61, 226–230. 10.1001/archneur.61.2.226
    1. Bermel, R. A. , & Bakshi, R. (2006). The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurology, 5, 158–170. 10.1016/S1474-4422(06)70349-0
    1. Bode, F. J. , Stephan, M. , Suhling, H. , Pabst, R. , Straub, R. H. , Raber, K. A. , … von Horsten, S. (2008). Sex differences in a transgenic rat model of Huntington's disease: Decreased 17beta‐estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Human Molecular Genetics, 17, 2595–2609. 10.1093/hmg/ddn159
    1. Bookstein, F. L. (2001). “Voxel‐based morphometry” should not be used with imperfectly registered images. NeuroImage, 14, 1454–1462. 10.1006/nimg.2001.0770
    1. Branger, P. , Parienti, J. J. , Sormani, M. P. , & Defer, G. (2016). The effect of disease‐modifying drugs on brain atrophy in relapsing‐remitting multiple sclerosis: A meta‐analysis. PLoS ONE, 11, e0149685 10.1371/journal.pone.0149685
    1. Bush, G. , Luu, P. , & Posner, M. I. (2000). Cognitive and emotional influences in anterior cingulate cortex. Trends in Cognitive Sciences, 4, 215–222. 10.1016/S1364-6613(00)01483-2
    1. Bush, G. , Whalen, P. J. , Rosen, B. R. , Jenike, M. A. , McInerney, S. C. , & Rauch, S. L. (1998). The counting Stroop: An interference task specialized for functional neuroimaging–validation study with functional MRI. Human Brain Mapping, 6, 270–282. 10.1002/(SICI)1097-0193(1998)6:4<270::AID-HBM6>;2-0
    1. Calabrese, M. , Atzori, M. , Bernardi, V. , Morra, A. , Romualdi, C. , Rinaldi, L. , … Gallo, P. (2007). Cortical atrophy is relevant in multiple sclerosis at clinical onset. Journal of Neurology, 254, 1212–1220. 10.1007/s00415-006-0503-6
    1. Calabrese, M. , Bernardi, V. , Atzori, M. , Mattisi, I. , Favaretto, A. , Rinaldi, F. , … Gallo, P. (2012). Effect of disease‐modifying drugs on cortical lesions and atrophy in relapsing‐remitting multiple sclerosis. Multiple Sclerosis, 18, 418–424. 10.1177/1352458510394702
    1. Calabrese, M. , De Stefano, N. , Atzori, M. , Bernardi, V. , Mattisi, I. , Barachino, L. , … Gallo, P. (2007). Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Archives of Neurology, 64, 1416–1422. 10.1001/archneur.64.10.1416
    1. Ceccarelli, A. , Jackson, J. S. , Tauhid, S. , Arora, A. , Gorky, J. , Dell'Oglio, E. , … Neema, M. (2012). The impact of lesion in‐painting and registration methods on voxel‐based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. American Journal of Neuroradiology, 33, 1579–1585. 10.3174/ajnr.A3083
    1. Ceccarelli, A. , Rocca, M. A. , Pagani, E. , Colombo, B. , Martinelli, V. , Comi, G. , & Filippi, M. (2008). A voxel‐based morphometry study of grey matter loss in MS patients with different clinical phenotypes. NeuroImage, 42, 315–322. 10.1016/j.neuroimage.2008.04.173
    1. Chard, D. T. , Griffin, C. M. , Parker, G. J. , Kapoor, R. , Thompson, A. J. , & Miller, D. H. (2002). Brain atrophy in clinically early relapsing‐remitting multiple sclerosis. Brain, 125, 327–337. 10.1093/brain/awf025
    1. Chard, D. T. , Griffin, C. M. , Rashid, W. , Davies, G. R. , Altmann, D. R. , Kapoor, R. , … Miller, D. H. (2004). Progressive grey matter atrophy in clinically early relapsing‐remitting multiple sclerosis. Multiple Sclerosis, 10, 387–391. 10.1191/1352458504ms1050oa
    1. Chard, D. T. , Jackson, J. S. , Miller, D. H. , & Wheeler‐Kingshott, C. A. (2010). Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. Journal of Magnetic Resonance Imaging, 32, 223–228. 10.1002/jmri.22214
    1. Charil, A. , Dagher, A. , Lerch, J. P. , Zijdenbos, A. P. , Worsley, K. J. , & Evans, A. C. (2007). Focal cortical atrophy in multiple sclerosis: Relation to lesion load and disability. NeuroImage, 34, 509–517. 10.1016/j.neuroimage.2006.10.006
    1. Chiaravalloti, N. D. , & DeLuca, J. (2008). Cognitive impairment in multiple sclerosis. Lancet Neurology, 7, 1139–1151. 10.1016/S1474-4422(08)70259-X
    1. Ciampi, E. , Pareto, D. , Sastre‐Garriga, J. , Vidal‐Jordana, A. , Tur, C. , Rio, J. , … Montalban, X. (2017). Grey matter atrophy is associated with disability increase in natalizumab‐treated patients. Multiple Sclerosis, 23, 556–566. 10.1177/1352458516656808
    1. Cohen, J. A. , Coles, A. J. , Arnold, D. L. , Confavreux, C. , Fox, E. J. , Hartung, H. P. , … CARE‐MS I investigators . (2012). Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet, 380, 1819–1828. 10.1016/S0140-6736(12)61769-3
    1. Coles, A. J. , Twyman, C. L. , Arnold, D. L. , Cohen, J. A. , Confavreux, C. , Fox, E. J. , … CARE‐MS II Investigators . (2012). Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: A randomised controlled phase 3 trial. Lancet, 380, 1829–1839. 10.1016/S0140-6736(12)61768-1
    1. Crawford, D. K. , Mangiardi, M. , Song, B. , Patel, R. , Du, S. , Sofroniew, M. V. , … Tiwari‐Woodruff, S. K. (2010). Oestrogen receptor beta ligand: A novel treatment to enhance endogenous functional remyelination. Brain, 133, 2999–3016. 10.1093/brain/awq237
    1. Cuadra, M. B. , Cammoun, L. , Butz, T. , Cuisenaire, O. , & Thiran, J. P. (2005). Comparison and validation of tissue modelization and statistical classification methods in T1‐weighted MR brain images. IEEE Transactions on Medical Imaging, 24, 1548–1565. 10.1109/TMI.2005.857652
    1. Dalton, C. M. , Chard, D. T. , Davies, G. R. , Miszkiel, K. A. , Altmann, D. R. , Fernando, K. , … Miller, D. H. (2004). Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain, 127, 1101–1107. 10.1093/brain/awh126
    1. Davatzikos, C. (2004). Why voxel‐based morphometric analysis should be used with great caution when characterizing group differences. NeuroImage, 23, 17–20. 10.1016/j.neuroimage.2004.05.010
    1. De Stefano, N. , Matthews, P. M. , Filippi, M. , Agosta, F. , De Luca, M. , Bartolozzi, M. L. , … Smith, S. M. (2003). Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability. Neurology, 60, 1157–1162. 10.1212/01.WNL.0000055926.69643.03
    1. Deloire, M. S. , Ruet, A. , Hamel, D. , Bonnet, M. , Dousset, V. , & Brochet, B. (2011). MRI predictors of cognitive outcome in early multiple sclerosis. Neurology, 76, 1161–1167. 10.1212/WNL.0b013e318212a8be
    1. van den Elskamp, I. J. , Boden, B. , Dattola, V. , Knol, D. L. , Filippi, M. , Kappos, L. , … Barkhof, F. (2010). Cerebral atrophy as outcome measure in short‐term phase 2 clinical trials in multiple sclerosis. Neuroradiology, 52, 875–881. 10.1007/s00234-009-0645-1
    1. Engler‐Chiurazzi, E. B. , Brown, C. M. , Povroznik, J. M. , & Simpkins, J. W. (2017). Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury. Progress in Neurobiology, 157, 188–211. 10.1016/j.pneurobio.2015.12.008
    1. Fisher, E. , Lee, J. C. , Nakamura, K. , & Rudick, R. A. (2008). Gray matter atrophy in multiple sclerosis: A longitudinal study. Annals of Neurology, 64, 255–265. 10.1002/ana.21436
    1. Fisher, E. , Rudick, R. A. , Simon, J. H. , Cutter, G. , Baier, M. , Lee, J. C. , … Simonian, N. A. (2002). Eight‐year follow‐up study of brain atrophy in patients with MS. Neurology, 59, 1412–1420. 10.1212/01.WNL.0000036271.49066.06
    1. Friston, K. J. , & Ashburner, J. (2004). Generative and recognition models for neuroanatomy. NeuroImage, 23, 21–24. 10.1016/j.neuroimage.2004.04.021
    1. Glaser, D. , & Friston, K. (2007). Covariance Components In Friston K., Ashburner J., Kiebel S., Nichols T. E., & Penny W. D. (Eds.), Statistical parametric mapping: The analysis of functional brain images (pp. 140–147). London, UK: Elsevier; 10.1016/B978-012372560-8/50010-3
    1. Gold, S. M. , Sasidhar, M. V. , Morales, L. B. , Du, S. , Sicotte, N. L. , Tiwari‐Woodruff, S. K. , & Voskuhl, R. R. (2009). Estrogen treatment decreases matrix metalloproteinase (MMP)‐9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Laboratory Investigation, 89, 1076–1083. 10.1038/labinvest.2009.79
    1. Gonzalez‐Rosa, J. J. , Vazquez‐Marrufo, M. , Vaquero, E. , Duque, P. , Borges, M. , Gamero, M. A. , … Izquierdo, G. (2006). Differential cognitive impairment for diverse forms of multiple sclerosis. BMC Neuroscience, 7, 39 10.1186/1471-2202-7-39
    1. Hochberg, Y. , & Benjamini, Y. (1990). More powerful procedures for multiple significance testing. Statistics in Medicine, 9, 811–818. 10.1002/(ISSN)1097-0258
    1. Itoh, N. , Kim, R. , Peng, M. , DiFilippo, E. , Johnsonbaugh, H. , MacKenzie‐Graham, A. , & Voskuhl, R. R. (2017). Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis. Journal of Neuroimmunology, 304, 63–71. 10.1016/j.jneuroim.2016.09.017
    1. Itoh, N. , Itoh, Y. , Tassoni, A. , Ren, E. , Kaito, M. , Ohno, A. , … Voskuhl, R. R. (2018). Cell‐specific and region‐specific transcriptomics in the multiple sclerosis model: Focus on astrocytes. Proceedings of the National Academy of Sciences of the United States of America, 115, E302–E309. 10.1073/pnas.1716032115
    1. Kantarci, K. , Tosakulwong, N. , Lesnick, T. G. , Zuk, S. M. , Lowe, V. J. , Fields, J. A. , … Miller, V. M. (2018). Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology, 90, e1404–e1412. 10.1212/WNL.0000000000005325
    1. Kappos, L. , Radue, E. W. , O'Connor, P. , Polman, C. , Hohlfeld, R. , Calabresi, P. , … FREEDOMS Study Group . (2010). A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine, 362, 387–401. 10.1056/NEJMoa0909494
    1. Kim, R. Y. , Mangu, D. , Hoffman, A. S. , Kavosh, R. , Jung, E. , Itoh, N. , & Voskuhl, R. (2018). Oestrogen receptor β ligand acts on CD11c+ cells to mediate protection in experimental autoimmune encephalomyelitis. Brain, 141, 132–147. 10.1093/brain/awx315
    1. Kurth, F. , Luders, E. , Sicotte, N. L. , Gaser, C. , Giesser, B. S. , Swerdloff, R. S. , … Mackenzie‐Graham, A. (2014). Neuroprotective effects of testosterone treatment in men with multiple sclerosis. NeuroImage Clinical, 4, 454–460. 10.1016/j.nicl.2014.03.001
    1. Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33, 1444–1452. 10.1212/WNL.33.11.1444
    1. Kutzelnigg, A. , Lucchinetti, C. F. , Stadelmann, C. , Bruck, W. , Rauschka, H. , Bergmann, M. , … Lassmann, H. (2005). Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain, 128, 2705–2712. 10.1093/brain/awh641
    1. Lublin, F. , Miller, D. H. , Freedman, M. S. , Cree, B. A. , Wolinsky, J. S. , Weiner, H. , … INFORMS Study Investigators . (2016). Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double‐blind, placebo‐controlled trial. Lancet, 387, 1075–1084. 10.1016/S0140-6736(15)01314-8
    1. Lublin, F. D. , & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology, 46, 907–911. 10.1212/WNL.46.4.907
    1. Luders, E. , Gaser, C. , Narr, K. L. , & Toga, A. W. (2009). Why sex matters: Brain size independent differences in gray matter distributions between men and women. Journal of Neuroscience, 29, 14265–14270. 10.1523/JNEUROSCI.2261-09.2009
    1. MacKenzie‐Graham, A. , Kurth, F. , Itoh, Y. , Wang, H. J. , Montag, M. J. , Elashoff, R. , & Voskuhl, R. R. (2016). Disability‐specific atlases of gray matter loss in relapsing‐remitting multiple sclerosis. JAMA Neurology, 73, 944–953. 10.1001/jamaneurol.2016.0966
    1. MacKenzie‐Graham, A. J. , Rinek, G. A. , Avedisian, A. , Morales, L. B. , Umeda, E. , Boulat, B. , … Voskuhl, R. R. (2012). Estrogen treatment prevents gray matter atrophy in experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 90, 1310–1323. 10.1002/jnr.23019
    1. Manjon, J. V. , Coupe, P. , Marti‐Bonmati, L. , Collins, D. L. , & Robles, M. (2010). Adaptive non‐local means denoising of MR images with spatially varying noise levels. Journal of Magnetic Resonance Imaging, 31, 192–203. 10.1002/jmri.22003
    1. Mattioli, F. , Stampatori, C. , Bellomi, F. , Scarpazza, C. , & Capra, R. (2015). Natalizumab significantly improves cognitive impairment over three years in MS: Pattern of disability progression and preliminary MRI findings. PLoS ONE, 10, e0131803 10.1371/journal.pone.0131803
    1. Miller, D. H. , Soon, D. , Fernando, K. T. , MacManus, D. G. , Barker, G. J. , Yousry, T. A. , … Sandrock, A. W. (2007). MRI outcomes in a placebo‐controlled trial of natalizumab in relapsing MS. Neurology, 68, 1390–1401. 10.1212/01.wnl.0000260064.77700.fd
    1. Morgen, K. , Sammer, G. , Courtney, S. M. , Wolters, T. , Melchior, H. , Blecker, C. R. , … Vaitl, D. (2006). Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing‐remitting MS. NeuroImage, 30, 891–898. 10.1016/j.neuroimage.2005.10.032
    1. Morissette, M. , Al Sweidi, S. , Callier, S. , & Di Paolo, T. (2008). Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Molecular and Cellular Endocrinology, 290, 60–69. 10.1016/j.mce.2008.04.008
    1. Petersen, S. E. , & Posner, M. I. (2012). The attention system of the human brain: 20 years after. Annual Review of Neuroscience, 35, 73–89. 10.1146/annurev-neuro-062111-150525
    1. Peterson, J. W. , Bo, L. , Mork, S. , Chang, A. , & Trapp, B. D. (2001). Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Annals of Neurology, 50, 389–400. 10.1002/ana.1123
    1. Pirko, I. , Lucchinetti, C. F. , Sriram, S. , & Bakshi, R. (2007). Gray matter involvement in multiple sclerosis. Neurology, 68, 634–642. 10.1212/01.wnl.0000250267.85698.7a
    1. Polman, C. , Barkhof, F. , Sandberg‐Wollheim, M. , Linde, A. , Nordle, O. , & Nederman, T. (2005). Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology, 64, 987–991. 10.1212/01.WNL.0000154520.48391.69
    1. Posner, M. I. , & Petersen, S. E. (1990). The attention system of the human brain. Annual Review of Neuroscience, 13, 25–42. 10.1146/annurev.ne.13.030190.000325
    1. Rajapakse, J. C. , Giedd, J. N. , & Rapoport, J. L. (1997). Statistical approach to segmentation of single‐channel cerebral MR images. IEEE Transactions on Medical Imaging, 16, 176–186. 10.1109/42.563663
    1. Rao, S. M. , Leo, G. J. , Bernardin, L. , & Unverzagt, F. (1991). Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology, 41, 685–691. 10.1212/WNL.41.5.685
    1. Raz, E. , Cercignani, M. , Sbardella, E. , Totaro, P. , Pozzilli, C. , Bozzali, M. , & Pantano, P. (2010). Gray‐ and white‐matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. Radiology, 257, 448–454. 10.1148/radiol.10100626
    1. Rinaldi, F. , Calabrese, M. , Seppi, D. , Puthenparampil, M. , Perini, P. , & Gallo, P. (2012). Natalizumab strongly suppresses cortical pathology in relapsing‐remitting multiple sclerosis. Multiple Sclerosis, 18, 1760–1767. 10.1177/1352458512447704
    1. Sailer, M. , Fischl, B. , Salat, D. , Tempelmann, C. , Schonfeld, M. A. , Busa, E. , … Dale, A. (2003). Focal thinning of the cerebral cortex in multiple sclerosis. Brain, 126, 1734–1744. 10.1093/brain/awg175
    1. Sanfilipo, M. P. , Benedict, R. H. , Sharma, J. , Weinstock‐Guttman, B. , & Bakshi, R. (2005). The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction. NeuroImage, 26, 1068–1077. 10.1016/j.neuroimage.2005.03.008
    1. Sanfilipo, M. P. , Benedict, R. H. , Weinstock‐Guttman, B. , & Bakshi, R. (2006). Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology, 66, 685–692. 10.1212/01.wnl.0000201238.93586.d9
    1. Shallice, T. , Stuss, D. T. , Alexander, M. P. , Picton, T. W. , & Derkzen, D. (2008). The multiple dimensions of sustained attention. Cortex, 44, 794–805. 10.1016/j.cortex.2007.04.002
    1. Sicotte, N. L. , Liva, S. M. , Klutch, R. , Pfeiffer, P. , Bouvier, S. , Odesa, S. , … Voskuhl, R. R. (2002). Treatment of multiple sclerosis with the pregnancy hormone estriol. Annals of Neurology, 52, 421–428. 10.1002/(ISSN)1531-8249
    1. Solari, A. , Radice, D. , Manneschi, L. , Motti, L. , & Montanari, E. (2005). The multiple sclerosis functional composite: Different practice effects in the three test components. Journal of the Neurological Sciences, 228, 71–74. 10.1016/j.jns.2004.09.033
    1. Soldan, S. S. , Alvarez Retuerto, A. I. , Sicotte, N. L. , & Voskuhl, R. R. (2003). Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. Journal of Immunology, 171, 6267–6274. 10.4049/jimmunol.171.11.6267
    1. Spence, R. D. , Hamby, M. E. , Umeda, E. , Itoh, N. , Du, S. , Wisdom, A. J. , … Voskuhl, R. R. (2011). Neuroprotection mediated through estrogen receptor‐alpha in astrocytes. Proceedings of the National Academy of Sciences of the United States of America, 108, 8867–8872. 10.1073/pnas.1103833108
    1. Spence, R. D. , & Voskuhl, R. R. (2012). Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Frontiers in Neuroendocrinology, 33, 105–115. 10.1016/j.yfrne.2011.12.001
    1. Suzuki, S. , Brown, C. M. , & Wise, P. M. (2009). Neuroprotective effects of estrogens following ischemic stroke. Frontiers in Neuroendocrinology, 30, 201–211. 10.1016/j.yfrne.2009.04.007
    1. Taillan, J. , Ardiale, E. , Anton, J. L. , Nazarian, B. , Felician, O. , & Lemaire, P. (2015). Processes in arithmetic strategy selection: A fMRI study. Frontiers in Psychology, 6, 61.
    1. Tekok‐Kilic, A. , Benedict, R. H. , Weinstock‐Guttman, B. , Dwyer, M. G. , Carone, D. , Srinivasaraghavan, B. , … Zivadinov, R. (2007). Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. NeuroImage, 36, 1294–1300. 10.1016/j.neuroimage.2007.04.017
    1. Tiberio, M. , Chard, D. T. , Altmann, D. R. , Davies, G. , Griffin, C. M. , Rashid, W. , … Miller, D. H. (2005). Gray and white matter volume changes in early RRMS: A 2‐year longitudinal study. Neurology, 64, 1001–1007. 10.1212/01.WNL.0000154526.22878.30
    1. Tohka, J. , Zijdenbos, A. , & Evans, A. (2004). Fast and robust parameter estimation for statistical partial volume models in brain MRI. NeuroImage, 23, 84–97. 10.1016/j.neuroimage.2004.05.007
    1. Tombaugh, T. N. (2006). A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Archives of Clinical Neuropsychology, 21, 53–76. 10.1016/j.acn.2005.07.006
    1. Valsasina, P. , Benedetti, B. , Rovaris, M. , Sormani, M. P. , Comi, G. , & Filippi, M. (2005). Evidence for progressive gray matter loss in patients with relapsing‐remitting MS. Neurology, 65, 1126–1128. 10.1212/01.wnl.0000178982.53965.70
    1. Voskuhl, R. R. , & Gold, S. M. (2012). Sex‐related factors in multiple sclerosis susceptibility and progression. Nature Reviews Neurology, 8, 255–263. 10.1038/nrneurol.2012.43
    1. Voskuhl, R. R. , Wang, H. , Wu, T. C. , Sicotte, N. L. , Nakamura, K. , Kurth, F. , … Elashoff, R. (2016). Estriol combined with glatiramer acetate for women with relapsing‐remitting multiple sclerosis: A randomised, placebo‐controlled, phase 2 trial. Lancet Neurology, 15, 35–46. 10.1016/S1474-4422(15)00322-1
    1. Wen, J. , Yablonskiy, D. A. , Luo, J. , Lancia, S. , Hildebolt, C. , & Cross, A. H. (2015). Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI. NeuroImage Clinical, 9, 164–175. 10.1016/j.nicl.2015.08.003
    1. Yue, X. , Lu, M. , Lancaster, T. , Cao, P. , Honda, S. , Staufenbiel, M. , … Li, R. (2005). Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proceedings of the National Academy of Sciences of the United States of America, 102, 19198–19203. 10.1073/pnas.0505203102
    1. Ziehn, M. O. , Avedisian, A. A. , Dervin, S. M. , O'Dell, T. J. , & Voskuhl, R. R. (2012). Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. Laboratory Investigation, 92, 1234–1245. 10.1038/labinvest.2012.76

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj